PF-06410293

BIOLOGICAL4 trials

Sponsors

Pfizer

Conditions

HealthyHealthy SubjectsRheumatoid Arthritis

Phase 1

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

CompletedNCT01870986

Start: 2013-05-31End: 2014-02-28Updated: 2014-02-14

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

CompletedNCT02237729

PfizerHealthy Subjects

Start: 2014-09-30End: 2015-03-31Updated: 2015-04-13

Phase 3

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

CompletedNCT02480153

PfizerRheumatoid Arthritis

Start: 2015-06-25End: 2017-12-06Updated: 2019-01-23

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

CompletedNCT04230213

PfizerRheumatoid Arthritis

Start: 2020-01-13End: 2021-06-22Updated: 2024-02-22

Related Papers

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.

2023-08-218 citations

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

RMD Open2022-09-011 citations

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

2022-03-184 citations

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Arthritis Research & Therapy2021-09-2515 citations

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

RMD Open2021-04-0118 citations

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.

2020-12-0134 citations

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

2018-08-1541 citations

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations